NASDAQ:NKTR Nektar Therapeutics (NKTR) Stock Price, News & Analysis $24.59 -1.25 (-4.84%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$24.20 -0.39 (-1.59%) As of 07/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Nektar Therapeutics Stock (NASDAQ:NKTR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nektar Therapeutics alerts:Sign Up Key Stats Today's Range$24.19▼$25.7450-Day Range$8.51▼$29.6852-Week Range$6.48▼$37.38Volume3.85 million shsAverage Volume464,616 shsMarket Capitalization$305.16 millionP/E RatioN/ADividend YieldN/APrice Target$84.17Consensus RatingBuy Company Overview Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California. Read More Nektar Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreNKTR MarketRank™: Nektar Therapeutics scored higher than 92% of companies evaluated by MarketBeat, and ranked 87th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNektar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNektar Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Nektar Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nektar Therapeutics are expected to decrease in the coming year, from ($0.72) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nektar Therapeutics is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nektar Therapeutics is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNektar Therapeutics has a P/B Ratio of 4.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nektar Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.98% of the float of Nektar Therapeutics has been sold short.Short Interest Ratio / Days to CoverNektar Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nektar Therapeutics has recently decreased by 20.95%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNektar Therapeutics does not currently pay a dividend.Dividend GrowthNektar Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.77 Percentage of Shares Shorted4.98% of the float of Nektar Therapeutics has been sold short.Short Interest Ratio / Days to CoverNektar Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nektar Therapeutics has recently decreased by 20.95%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News Sentiment0.89 News SentimentNektar Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Nektar Therapeutics this week, compared to 5 articles on an average week.Search Interest35 people have searched for NKTR on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows6 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,416.00 in company stock.Percentage Held by InsidersOnly 3.71% of the stock of Nektar Therapeutics is held by insiders.Percentage Held by Institutions75.88% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nektar Therapeutics' insider trading history. Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NKTR Stock News HeadlinesBiotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsWith major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?June 30 at 2:21 PM | marketbeat.comNektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.June 28, 2025 | marketbeat.comBanks aren’t ready for this altcoin—are you?Want to see why we believe this could be the next evolution of financial infrastructure? The old financial system is showing cracks—and this altcoin might be ready to take its place | Crypto 101 Media (Ad)Nektar Therapeutics Announces Public Offering of SharesJuly 1 at 4:57 PM | tipranks.comNektar Therapeutics stock dips after pricing $100M stock offeringJuly 1 at 8:19 AM | seekingalpha.comNektar Therapeutics Announces Pricing of $100 Million Public OfferingJuly 1 at 7:17 AM | prnewswire.comNektar Therapeutics launches proposed public offeringJune 30 at 6:42 PM | msn.comNektar Therapeutics stock falls after announcing public offeringJune 30 at 6:42 PM | in.investing.comSee More Headlines NKTR Stock Analysis - Frequently Asked Questions How have NKTR shares performed this year? Nektar Therapeutics' stock was trading at $13.95 on January 1st, 2025. Since then, NKTR stock has increased by 76.3% and is now trading at $24.59. View the best growth stocks for 2025 here. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) announced its earnings results on Thursday, May, 8th. The biopharmaceutical company reported ($3.30) earnings per share for the quarter, missing analysts' consensus estimates of ($2.70) by $0.60. The biopharmaceutical company had revenue of $10.46 million for the quarter, compared to the consensus estimate of $15.61 million. Nektar Therapeutics had a negative net margin of 152.49% and a negative trailing twelve-month return on equity of 329.54%. Read the conference call transcript. When did Nektar Therapeutics' stock split? Shares of Nektar Therapeutics reverse split on the morning of Monday, June 9th 2025.A 1-15 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, June 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Nektar Therapeutics? Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nektar Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Bristol Myers Squibb (BMY), Netflix (NFLX) and Exxon Mobil (XOM). Company Calendar Last Earnings5/08/2025Today7/01/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NKTR CIK906709 Webwww.nektar.com Phone(415) 482-5300Fax415-339-5300Employees220Year Founded1990Price Target and Rating Average Stock Price Target$84.17 High Stock Price Target$120.00 Low Stock Price Target$30.00 Potential Upside/Downside+241.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($9.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$118.96 million Net Margins-152.49% Pretax Margin-147.55% Return on Equity-329.54% Return on Assets-55.24% Debt Debt-to-Equity RatioN/A Current Ratio3.24 Quick Ratio3.24 Sales & Book Value Annual Sales$98.43 million Price / Sales3.11 Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book4.99Miscellaneous Outstanding Shares12,410,000Free Float11,947,000Market Cap$305.78 million OptionableOptionable Beta0.55 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:NKTR) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.